An MDMA analogue which could end up in direct competition with...

  1. 1,721 Posts.
    lightbulb Created with Sketch. 541
    An MDMA analogue which could end up in direct competition with Emyria's own ones. Very strange.

    All to generate some professional fees. Emeryia has changed so much from a promising biotech to a clinical service provider.
    Last edited by reon1: 20/06/24
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
2.8¢
Change
0.001(3.70%)
Mkt cap ! $17.12M
Open High Low Value Volume
2.7¢ 2.8¢ 2.7¢ $35.58K 1.315M

Buyers (Bids)

No. Vol. Price($)
2 302281 2.7¢
 

Sellers (Offers)

Price($) Vol. No.
2.8¢ 768032 2
View Market Depth
Last trade - 16.10pm 04/07/2025 (20 minute delay) ?
EMD (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.